Clinical Trial Update: Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating two dose levels of NX-1207 for low-risk, localized prostate cancer (T1c); the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• NX-1207

Snippet

Sponsor: Nymox Corporation | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED